Meet online with researchers from the four federally-funded Clinical and Translational Science programs in Massachusetts to hear about how they are working together to protect us from COVID-19
COVID-19 Research Community Second Forum:
RNA Therapeutics: Informational Drugs as a Pandemic Response Tool
Anastasia Khvorova, PhD UMass Center for Clinical and Translational Science (UMCCTS)
Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Public Health Needs
National Center for Advancing Translational Sciences (NCATS)
Availability of Administrative Supplements and Urgent Competitive Revisions for the Establishment and Maintenance of a Research Database for Neurological Manifestations of the SARS-CoV-2
National Institute of Neurological Disorders and Stroke (NINDS)
Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences
A panel of U.S. physicians, statisticians, and other experts has developed treatment guidelines for coronavirus disease 2019 (COVID-19). These guidelines, intended for healthcare providers, are based on published and preliminary data and the clinical expertise of the panelists, many of whom are frontline clinicians caring for patients during the rapidly evolving pandemic.
The Outcomes Related to COVID-19 treated with hydroxychloroquine among In-patients with symptomatic Disease study, or ORCHID Study, is being conducted by the Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network of the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
